A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Trial Profile

A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Duvelisib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FRESCO
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 28 Jul 2017 Status changed to withdrawn prior to enrolment as sponsor is focusing on studies which can enable registration of duvelisib
    • 09 Jan 2017 Status changed from recruiting to discontinued.
    • 27 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top